Articles – Generic Peptides

Explore research-focused peptide articles designed to make complex compounds, safety considerations, and emerging peptide science easier to understand.

CJC-1295/Ipamorelin: Popular Duo-Blend in 2026 Regulatory Limbo

CJC-1295 / Ipamorelin Duo-Blend Mechanism, Side Effects, FDA Status in 2026: Complete Clinical Review of the 5mg/5mg Combination Stack, 10x Synergistic GH Release, and PCAC Reclassification Path By Medical Team of Generic Peptides The CJC-1295/Ipamorelin Duo-…

Epitalon: Longevity Tetrapeptide With 2026 FDA PCAC Review

Epitalon (AEDG) Mechanism, Side Effects, TFDA Status in 2026: Complete Clinical Review of the Pineal Tetrapeptide, 25 Years of Khavinson Research, 2025 Independent Replication, and July 24 PCAC Reclassification Vote By Medical Team of Generic Peptides Epitalo…

DSIP: 1977 Swiss-Discovered Sleep Peptide Facing 2026 PCAC Review

DSIP / Emideltide (Delta Sleep-Inducing Peptide) Guide 2026: Side Effects, Mechanism, Sleep Architecture Effects, FDA Status, and July 24 PCAC Vote for Insomnia, Opioid Withdrawal, and Narcolepsy By Medical Team of Generic Peptides DSIP (Delta Sleep-Inducing …

AOD-9604: GH Fragment Central to 2026 Peptide Reclassification

AOD-9604 Mechanism, Side Effects, Fat Loss Effects & FDA Status in 2026: Complete Clinical Review of the hGH Fragment, β3-Adrenergic Activation, Phase IIb Trial Results, and the July 23 PCAC Reclassification Vote By Medical Team of Generic Peptides AOD-9604 i…

Adipotide: Fat-Targeted Peptide and the Missing Human Trial

Adipotide Mechanism, Side Effects, FDA Status in 2026: Complete Clinical Review of the Hunter-Killer Peptide, Prohibitin-Targeted Vascular Disruption, Primate Trial Results, and the 2019 Phase I Termination Mystery By Medical Team of Generic Peptides Adipotid…